Profusa, Inc. Provides Strategy Overview and Business Update for Investors
Profusa (NASDAQ: PFSA), a digital health company, has provided a comprehensive business update following its recent Nasdaq listing on July 14, 2025. The company outlined five strategic pillars: revenue growth, AI infrastructure, clinical/regulatory pathways, financial structure, and operational scale.
Key developments include: $100 million ELOC facility secured for growth funding, planned European launch of Lumee鈩� platform for tissue oxygen monitoring in Q1 2026, targeting a $10 billion global addressable market. The company aims for U.S. FDA submission mid-2026 with commercialization expected in 2027. Their glucose monitoring platform, addressing a 500 million patient market, is progressing with human validation data expected from EU and APAC clinical sites, targeting commercialization by mid-2027.
Profusa (NASDAQ: PFSA), un'azienda nel settore della salute digitale, ha fornito un aggiornamento completo sulle attivit脿 aziendali dopo la sua recente quotazione al Nasdaq il 14 luglio 2025. La societ脿 ha delineato cinque pilastri strategici: crescita dei ricavi, infrastruttura AI, percorsi clinici/regolatori, struttura finanziaria e scala operativa.
Tra gli sviluppi principali si evidenziano: una linea di credito ELOC da 100 milioni di dollari garantita per finanziare la crescita, il lancio previsto in Europa della piattaforma Lumee鈩� per il monitoraggio dell鈥檕ssigeno nei tessuti nel primo trimestre 2026, con un mercato globale indirizzabile da 10 miliardi di dollari. L鈥檃zienda punta alla presentazione alla FDA statunitense a met脿 2026 con una commercializzazione prevista per il 2027. La piattaforma per il monitoraggio del glucosio, che si rivolge a un mercato di 500 milioni di pazienti, sta avanzando con dati di validazione umana attesi da siti clinici in UE e APAC, con l鈥檕biettivo di commercializzazione entro met脿 2027.
Profusa (NASDAQ: PFSA), una empresa de salud digital, ha proporcionado una actualizaci贸n integral del negocio tras su reciente cotizaci贸n en Nasdaq el 14 de julio de 2025. La compa帽铆a destac贸 cinco pilares estrat茅gicos: crecimiento de ingresos, infraestructura de IA, v铆as cl铆nicas/regulatorias, estructura financiera y escala operativa.
Los desarrollos clave incluyen: una l铆nea de cr茅dito ELOC de 100 millones de d贸lares asegurada para financiar el crecimiento, el lanzamiento planeado en Europa de la plataforma Lumee鈩� para el monitoreo de ox铆geno tisular en el primer trimestre de 2026, apuntando a un mercado global direccionable de 10 mil millones de d贸lares. La empresa tiene como objetivo presentar a la FDA de EE.UU. a mediados de 2026 y espera la comercializaci贸n en 2027. Su plataforma de monitoreo de glucosa, que atiende a un mercado de 500 millones de pacientes, est谩 avanzando con datos de validaci贸n humana esperados de sitios cl铆nicos en la UE y APAC, con la meta de comercializaci贸n para mediados de 2027.
Profusa (NASDAQ: PFSA)電� 霐旍韯� 項姢 旮办梾鞙茧, 2025雲� 7鞗� 14鞚� 雮橃姢雼� 靸侅灔 鞚错泟 韽磩鞝侅澑 靷梾 鞐呺嵃鞚错姼毳� 鞝滉车頄堨姷雼堧嫟. 須岇偓電� 雼れ劘 臧�歆� 鞝勲灥鞝� 旮半懃鞚� 鞝滌嫓頄堨姷雼堧嫟: 靾橃澋 靹膘灔, AI 鞚疙攧霛�, 鞛勳儊/攴滌牅 瓴诫, 鞛 甑“, 鞖挫榿 攴滊.
欤检殧 臧滊皽 靷暛鞙茧電� 靹膘灔 鞛愱笀 頇曤炒毳� 鞙勴暅 1鞏� 雼煬 ELOC 鞁滌劋 頇曤炒, 2026雲� 1攵勱赴 鞙犽熃鞐愳劀 臁办 靷办唽 氇媹韯半鞖� Lumee鈩� 頂岆灚韽� 於滌嫓 鞓堨爼, 100鞏� 雼煬 攴滊鞚� 旮�搿滊矊 欤检唽 歆�鞝� 鞁滌灔鞚� 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟. 須岇偓電� 2026雲� 欷戨皹 氙戈淡 FDA 鞝滌稖鞚� 氇╉憸搿� 頃橂┌ 2027雲� 靸侅毄頇旊ゼ 旮半寑頃橁碃 鞛堨姷雼堧嫟. 5鞏� 頇橃瀽 鞁滌灔鞚� 瓴儱頃� 雼� 氇媹韯半 頂岆灚韽检潃 EU 氚� APAC 鞛勳儊 靷澊韸胳棎靹� 鞚戈皠 瓴�歃� 雿办澊韯半ゼ 歆勴枆 欷戩澊氅�, 2027雲� 欷戨皹旯岇 靸侅毄頇旊ゼ 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
Profusa (NASDAQ : PFSA), une entreprise de sant茅 num茅rique, a fourni une mise 脿 jour compl猫te de ses activit茅s suite 脿 son introduction r茅cente au Nasdaq le 14 juillet 2025. La soci茅t茅 a pr茅sent茅 cinq piliers strat茅giques : croissance des revenus, infrastructure IA, parcours cliniques/r茅glementaires, structure financi猫re et 茅chelle op茅rationnelle.
Les d茅veloppements cl茅s incluent : une facilit茅 de cr茅dit ELOC de 100 millions de dollars s茅curis茅e pour financer la croissance, le lancement pr茅vu en Europe de la plateforme Lumee鈩� pour la surveillance de l鈥檕xyg猫ne tissulaire au premier trimestre 2026, visant un march茅 mondial adressable de 10 milliards de dollars. L鈥檈ntreprise vise une soumission 脿 la FDA am茅ricaine 脿 la mi-2026 avec une commercialisation attendue en 2027. Leur plateforme de surveillance du glucose, ciblant un march茅 de 500 millions de patients, progresse avec des donn茅es de validation humaine attendues des sites cliniques en UE et APAC, visant une commercialisation d鈥檌ci mi-2027.
Profusa (NASDAQ: PFSA), ein Unternehmen im Bereich digitale Gesundheit, hat ein umfassendes Gesch盲ftsupdate nach seiner k眉rzlichen Nasdaq-Notierung am 14. Juli 2025 ver枚ffentlicht. Das Unternehmen stellte f眉nf strategische S盲ulen vor: Umsatzwachstum, KI-Infrastruktur, klinische/regulatorische Wege, Finanzstruktur und operative Skalierung.
Wichtige Entwicklungen umfassen: eine gesicherte 100-惭颈濒濒颈辞苍别苍-顿辞濒濒补谤-贰尝翱颁-贵补锄颈濒颈迟盲迟 zur Wachstumsfinanzierung, den geplanten europ盲ischen Start der Lumee鈩�-Plattform zur Gewebe-Sauerstoff眉berwachung im ersten Quartal 2026 mit einem global adressierbaren Markt von 10 Milliarden Dollar. Das Unternehmen strebt eine FDA-Einreichung in den USA Mitte 2026 an, mit einer erwarteten Kommerzialisierung im Jahr 2027. Ihre Glukose眉berwachungsplattform, die einen Markt von 500 Millionen Patienten anspricht, macht Fortschritte mit erwarteten Validierungsdaten aus klinischen Standorten in der EU und APAC und zielt auf eine Kommerzialisierung bis Mitte 2027 ab.
- Secured $100 million ELOC facility for growth funding
- CE mark approval obtained for Lumee鈩� platform
- First distributor partnership established in Spain
- Targeting $10 billion global addressable market for tissue oxygen monitoring
- Glucose monitoring platform addresses potential market of 500 million patients
- Successfully listed on Nasdaq (PFSA) in July 2025
- Commercial revenue generation still in early stages
- U.S. market entry delayed until 2027
- Multiple regulatory approvals still pending
- Current stock price described as 'modest' by CEO
Insights
Profusa outlines post-IPO strategy with two key products targeting $10B oxygen monitoring and massive glucose monitoring markets by 2027.
This shareholder letter marks Profusa's transition from private to public markets, offering the first strategic roadmap following their July 14th NASDAQ listing. The company is developing an innovative subcutaneous biochemistry monitoring platform with significant market potential across multiple applications.
The core technology appears to be a subcutaneous filament that can continuously monitor various biochemical markers with AI integration for clinical insights. Their commercial strategy is organized around five pillars: revenue growth, AI infrastructure, clinical/regulatory pathways, financial structure, and operational scaling.
Two primary product pathways are emerging: 1) The Lumee鈩� platform for tissue oxygen monitoring has received CE mark approval with European commercialization targeted for Q1 2026. Profusa estimates a
The regulatory timeline shows methodical progression: European oxygen monitoring launch in Q1 2026, concurrent U.S. pivotal studies, FDA submission mid-2026, and U.S. commercialization by mid-2027. For glucose monitoring, human validation data is expected from clinical sites in EU and APAC, with pivotal studies in late 2026 and potential commercialization by mid-2027.
Financially, Profusa has secured a
While the letter presents an optimistic growth trajectory, investors should note the extended timeline to full commercialization of their key products, with major revenue generation likely not occurring until 2027. The company appears well-positioned in high-value markets, but execution across multiple complex regulatory pathways will be critical.
Profusa's biochemistry monitoring platform progressing with dual regulatory pathways for tissue oxygen and glucose monitoring through 2027.
Profusa's core innovation 鈥� a subcutaneous filament for continuous biochemistry monitoring 鈥� represents a potentially disruptive approach to healthcare diagnostics. Unlike traditional intermittent testing, this platform appears designed for constant monitoring with AI-enhanced data analysis, positioning it at the intersection of medical devices and digital health.
From a technical development perspective, the company has strategically prioritized tissue oxygen monitoring as their first commercial application, which makes sense as a market entry strategy. Oxygen sensing likely represents a less complex regulatory pathway than their glucose monitoring technology. The CE mark approval for the Lumee鈩� platform validates their initial regulatory approach and manufacturing standards.
What's particularly notable is their pipeline breadth beyond the initial applications. The letter mentions lactate, carbon dioxide, sodium, and ethanol monitoring capabilities in development. This suggests their sensing platform may be adaptable to different biomarkers through relatively modest modifications rather than complete redesigns. Such platform scalability, if achieved, would significantly enhance their commercial potential.
Their regulatory strategy appears methodically phased: using the European market as the initial commercial proving ground while pursuing the more demanding FDA pathway. This approach allows them to generate real-world clinical evidence and refine their commercial operations before tackling the U.S. market.
For the continuous glucose monitoring application, the timeline suggests they're still in clinical validation phases rather than pivotal studies. The planned 2026 pivotal studies indicate that significant technical and clinical work remains. The mid-2027 commercialization target for glucose monitoring appears optimistic but potentially achievable if validation data from current clinical sites proves compelling.
The distributed manufacturing and quality systems required to scale production of implantable medical devices represent significant operational challenges that weren't detailed in this update. As Profusa transitions from development to commercialization, their ability to establish robust manufacturing while maintaining quality compliance will be crucial for meeting their ambitious timeline.
BERKELEY, Calif, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (鈥淧rofusa鈥� or the 鈥淐ompany鈥�) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual鈥檚 biochemistry, provides a strategy overview and business update from Chairman and CEO, Ben Hwang, Ph.D. in the following Letter to Shareholders:
To our valued shareholders,
In the last two months, Profusa has achieved significant milestones, including securing investment and becoming a public company that is trading on the Nasdaq Market under the ticker PFSA on July 14, 2025. With these essential steps behind us, we are now fully committed to bring our groundbreaking personalized biochemistry technology platform to the clinical community and drive growth in our business. We believe that our technology represents a significant advancement from what is currently available today, not only because of its potential for multiple uses - from tissue oxygen to glucose biochemistry, but also the integrated AI and machine learning capabilities to derive personalized clinical insights, providing direction for coaching, statistical analysis, and optimization of treatment paradigms.
As we advance our programs, we have established five pillars that we believe will encompass our growth strategy, which we will use to guide our progress and shape our message. As we progress, our focus will be on 1) revenue growth and pipeline development, 2) AI infrastructure development, 3) clinical and regulatory pathways, 4) financial structure and strategies, and 5) scale of operations. We believe that organizing our activities in this way will help us best achieve our goals and ultimately maximize our shareholder value.
In thinking about our progress to date, on the revenue growth side, we are pleased to report that we are on our way to generating revenue from research use only applications of our technology platform, which will be immediately additive to our commercial operations. In addition, these research applications have the potential to continue to stretch the capabilities of our technology. We will further develop our pipeline through these research-only collaborations to facilitate聽聽 the pursuit of indications we aim to develop, which include lactate, carbon dioxide, sodium, and ethanol, among others, as we define future personalized healthcare applications of our technology.
In the meantime, within our clinical and regulatory pathway pillar and leveraging our CE mark approval, we are diligently progressing towards the European launch of our Lumee鈩� platform for tissue oxygen monitoring. Further, we continue to advance towards commercialization 鈥� with focus on our first pillar to drive revenue growth - having recently announced our first distributor partner in Spain, to achieve our target Q1 2026 commercial launch in Europe. We estimate an approximately
In terms of our continuous glucose monitoring platform, for which there is a total global addressable market of more than 500 million patients spanning both T2 and chronic, at-risk pre-diabetes patients, where we believe our technology will serve an important clinical need, we expect human validation data from two EU clinical sites and two APAC sites to be published in a peer reviewed journal. . We could expect human pivotal studies to commence later in 2026, with the goal of commercialization by mid-2027 following clearance of the appropriate regulatory pathways.
To secure our financial stability 鈥� within our financial strategies pillar, as previously announced, we are pleased to have secured a
From the perspective of scaling our operations pillar, we continue to expand our operating capabilities to be ready to scale to execute on our vision and look forward to providing some of these operational updates in due time.
We remain dedicated to bringing our game-changing technology to the clinical community, recognizing the potential this monitoring platform offers to a wide array of patients and users, including those with debilitating and/or chronic diseases, in addition to addressing the emerging questions of personalized healthcare and longevity. We believe we hold the keys to a bright future where a tiny filament injected subcutaneously can provide a wealth of information across an array of indications and are confident that our five pillars will provide the organization necessary to help us drive forward in a focused manner.聽聽
We also believe our management team and top-tier advisors are guiding the Company toward technological and financial achievement that transcends our current modest stock price. We sincerely thank our loyal investors for their continued support and warmly welcome those who have recently joined us, recognizing the value we aim to deliver. We also encourage dialogue with our investors, welcoming questions and feedback along the way to maintain transparency. We thank you all for sharing our values of innovation and optimism that together we can achieve a new age in digital health, and we look forward to traversing the future together.
Sincerely,
Ben Hwang, Ph.D.
CEO
Profusa, Inc.
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
鈥淟UMEE鈥�, 鈥淧ROFUSA鈥� and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit聽
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this 鈥淧ress Release鈥�) may be considered 鈥渇orward-looking statements鈥� within the meaning of the 鈥渟afe harbor鈥� provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渇orecast,鈥� 鈥渇uture,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減ossible,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥減ropose,鈥� 鈥渟eek,鈥� 鈥渟hould,鈥� 鈥渟trive,鈥� 鈥渨ill,鈥� or 鈥渨ould鈥� or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including risks regarding the highly volatile nature of the price of Bitcoin and other cryptocurrencies, as well as the risk that the Company's stock price may be highly correlated to the price of the digital assets that it holds. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and described in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts
email:
phone: 1 (212) 655-0924
FAQ
What are the five strategic pillars announced by Profusa (PFSA)?
When will Profusa (PFSA) launch its Lumee platform in Europe?
What is the market size for Profusa's glucose monitoring platform?
How much funding has Profusa (PFSA) secured through the ELOC facility?
When does Profusa expect FDA approval and U.S. commercialization?
